{
    "organizations": [],
    "uuid": "f8ad035d42b189806dbc5ce40fc88bd1ce64201d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-biogen-and-neurimmune-announce-opt/brief-biogen-and-neurimmune-announce-option-exercise-for-alzheimers-disease-investigational-treatment-aducanumab-idUSFWN1S807A",
    "ord_in_thread": 0,
    "title": "BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1, 2018 / 12:23 PM / Updated 25 minutes ago BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab Reuters Staff\nMay 1 (Reuters) - Biogen Inc:\n* BIOGEN AND NEURIMMUNE ANNOUNCE OPTION EXERCISE FOR ALZHEIMERâ€™S DISEASE INVESTIGATIONAL TREATMENT ADUCANUMAB\n* BIOGEN - WILL MAKE A ONE-TIME $50 MILLION PAYMENT TO NEURIMMUNE FOR 5% REDUCTION IN ORIGINAL ROYALTY RATES ON POTENTIAL COMMERCIAL SALES OF ADUCANUMAB\n* BIOGEN INC - HAS EXERCISED ITS OPTION TO FURTHER REDUCE PREVIOUSLY NEGOTIATED ROYALTY RATES PAYABLE ON POTENTIAL FUTURE SALES OF ADUCANUMAB Source text for Eikon: Further company coverage:",
    "published": "2018-05-01T15:23:00.000+03:00",
    "crawled": "2018-05-01T15:55:13.075+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "pm",
        "updated",
        "minute",
        "ago",
        "neurimmune",
        "announce",
        "option",
        "exercise",
        "alzheimer",
        "disease",
        "investigational",
        "treatment",
        "aducanumab",
        "reuters",
        "staff",
        "may",
        "reuters",
        "biogen",
        "inc",
        "biogen",
        "neurimmune",
        "announce",
        "option",
        "exercise",
        "alzheimer",
        "disease",
        "investigational",
        "treatment",
        "aducanumab",
        "biogen",
        "make",
        "million",
        "payment",
        "neurimmune",
        "reduction",
        "original",
        "royalty",
        "rate",
        "potential",
        "commercial",
        "sale",
        "aducanumab",
        "biogen",
        "inc",
        "exercised",
        "option",
        "reduce",
        "previously",
        "negotiated",
        "royalty",
        "rate",
        "payable",
        "potential",
        "future",
        "sale",
        "aducanumab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}